Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCPED1251


Supplemental Empiric Antibiotics in Unstable Febrile Neutropenia: Indications and Outcomes - CHART REVIEW

Principal Investigator(s)

Adam Esbenshade


  • Protocol No. VICCPED1251
  • Open Date: 05/31/2012
  • Staging: N/A
  • Age Group: Both Child and Adult
  • Scope: Local
  • Objective: Determine which symptoms traditionally associated with systemic compromise (hypotension change in mental status, rigors, and chills) best predict bacteremia in pediatric cancer patients presenting with neutropenic fever.
  • Disease Sites: Pediatrics
  • Therapies: None Specified
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: Not Specified


None Provided.


Not provided. Please call for more information.